(dr) Dermamatica
Dermamatica promises to accelerate early detection, through AI applied to image analysis. Creator fled the war in Ukraine.
O skin cancer It is a problem that has spread over the last few decades. Its incidence has increased drastically.
Data from the Portuguese Skin Cancer Association show that, in Portugal alone, 13,000 new cases of skin cancer appear per year.
The least common is melanona, with more than 1,000 new cases in a year. It is the least common type of skin cancer, but the most aggressive, reminds .
Anyone who has melanone, and if it is detected late, is almost a “death sentence”.
Therefore, the prevention is essential. As with so many other diseases.
It is in this context that the Dermamatic. The platform promises to accelerate the early detection of skin cancer through Artificial Intelligence (IA) applied to image analysis.
It was created in Portugal, at the Portuguese Catholic University. Its creator is Sam Izadloo, a medical student, born in Iran – but who grew up in Ukraine and was in the country when the war with Russia began.
Presented at this year’s Web Summit, Dermamatica was developed to support primary care doctors in their first patient contact.
From a photograph, generates a risk score (risk score) and a heat map (heatmap) that highlight the characteristics that led to the evaluation of AI.
The idea of this innovation is reduce referral delays and facilitate the identification of suspicious lesions, especially in contexts where access to dermatologists is limited.
In other words, the tool aims to speed up the patient journey and improve initial triage.
Instead of providing opaque predictions, Dermamatica offers interpretable results, helping clinicians understand why an injury may be suspicious and supporting more informed decisions, reads in da Católica.
Sam Izadloo clarifies that the explainability of the system is essential to building trust: “Doctors can understand why an injury is considered suspicious, which supports more informed decisions.”
Dermamatica is in the pilot phase. It will be made commercially available in Portugal after meeting regulatory requirements.
